NCT07275970进行中（未招募）1 期
An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD
Scottsdale Research Institute3 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年3月20日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Number/Incidence of adverse events (AEs), and serious adverse events (SAEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
研究概览
简要总结
This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals ≥ 18 years of age
- •Have a diagnosis of Post-Traumatic Stress Disorder (PTSD) as defined:
- •Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer as assessed by a study psychiatrist.
- •Determination of at least one traumatic event as determined by the LEC-5
- •A score of at least 33 on the PCL-5
- •Willing and able to provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Willingly agreed to provide verbal consent to provide needed pre-screening information, including medical history, concomitant medications, etc., prior to signing the ICF.
- •Be willing to commit to self-administering the study drug, to completing the QoL and PRO instruments, and attending all study visits.
- •Participants must be able to evaluate their average pain on the BPI (Brief Pain Inventory) over the past week.
- •Acceptable renal functioning as determined by no significant prior medical history and results of clinical laboratory evaluations done at Screening and on Day 1 (e.g., eGFR >45 (mL/min/1.73 m2))
- •Acceptable hepatic functioning as determined by no significant prior medical history and results of clinical laboratory evaluations done at Screening and on Day 1 (e.g., liver enzymes ≤1.5x the upper limit of normal, 'ULN')
- •Agree to only use the psilocybin mushroom provided by site staff and not use any other psilocybin (or similar drug) in any form for at least 30 days prior to Study Day 1 and for 30 days following the single-dose study drug treatment.
- •Is willing to wear, sync daily, and charge twice weekly a provisioned health tracking wearable device every day during sleep and daily activity. If the participant already has the same, or compatible device, they can use their own.
- •Agree to not use any psychoactive drugs, partake alcoholic beverages, self-administer ondansetron (or other selective serotonin reuptake inhibitors 'SSRIs', serotonin-norepinephrine reuptake inhibitors, 'SNRIs' and monoamine oxidase inhibits, 'MAOs'), cannabis, and/or any other non-routine PRN medications within 24 hours of Study Day
- •Exceptions include daily use of caffeine, nicotine, and opioid pain medication
- •Be stable on any pre-study medications and/or psychotherapy regimen prior to study entry. Agree to inform physician(s)/clinician(s) providing current care about your participation in the study (or permit the research site study staff to do so). Agree to report any changes in medication or psychotherapy treatment regimen during the study, to study staff.
- •If female and of childbearing potential, the participant is eligible for the trial only with a negative urine pregnancy test during Screening and on Study Day
- •[If a result is uncertain (e.g., potential false positive), a serum human chorionic gonadotropin (hHCG) test may be performed prior to the administration of the study drug.] Fertile females agree to use a highly effective form of birth control during the 30-day posttreatment period and must confirm that they have no intent to try to become pregnant or any need to breastfeed during this period.
- •Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, oral hormones plus a barrier contraception, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom and diaphragm, condom or diaphragm and spermicide, oral hormonal contraceptives and spermicide or condom). Not of childbearing potential is defined as permanent sterilization or postmenopausal females.
- •Be proficient in reading and writing in English and able to effectively communicate with site staff.
- •Agree not to participate in any other interventional clinical trials during the study.
排除标准
- •Currently uncontrolled hypertension. (>140/90 at Screening and >145/95 on Study Day 1).
- •History of recent seizure (within 3 months of Study Day 1).
- •History of stroke or transient ischemic attacks.
- •Preexisting history of valvulopathy or pulmonary hypertension.
- •A marked prolongation of QT interval (i.e., QT ≥450 msec) over a series of 3 ECGs performed within 5-6 minutes.
- •Currently uncontrolled diabetes (HbA1c > 8.0%).
- •Potential for adverse drug-drug interactions such as the use of centrally-acting serotonergic agents within 24 hours prior to and for 72 hours following study drug administration on Study Day
- •8. Significant suicide risk defined by (1) suicidal ideation as endorsed on items 4 or 5 on the Columbia Suicidal Severity Rating Scale (C-SSRS) within the last 6 months, at Screening, or at Baseline (Visit 1), or; (2) suicidal behaviors within the last 12 months as assessed by C-SSRS.
- •9. Patients with severe anxiety and depression measured as following: Participants with scores of 15 & above on Generalized Anxiety Disorder-7 (GAD-7) scale, and/or with scores of 20 & above on Patient Health Questionnaire-9 (PHQ -9).
- •10. Are pregnant or nursing or are women of childbearing potential who are not practicing a highly effective means of birth control.
- •11. Have any allergies or contraindication to psilocybin mushrooms.
- •Current users of psilocybin, LSD, DMT, Ayahuasca, Peyote, mescaline, and ketamine over the past 30 days will not qualify for the study unless the use of these agents is stopped for 30 days prior to Study Day 1 and the participant agrees to not use these (or similar) agents for 30 days after Study Day
- •13. Are not able to attend face-to-face visits at the study site or plan to move out of the area prior to the 3-month LTFU visit.
- •14. Have any current problem that, in the opinion of the Investigator or Medical Monitor, might interfere with an individual's participation in the study or confound the assessment of safety and/or efficacy of the study drug.
研究组 & 干预措施
30mg of psilocybin administered orally in a single dosing session
Experimental
干预措施: Psychedelic (Drug)
结局指标
主要结局
Number/Incidence of adverse events (AEs), and serious adverse events (SAEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
时间窗: From dosing to 3-month follow-up
Number/Incidence of Mental and Psychotic AE's
时间窗: From dosing to 3-month follow-up
次要结局
- Area Under the Curve (AUC₀-₈) for Psilocin(Pre-dose to 8 hours post-dose)
- Maximum Plasma Concentration (Cmax) of Psilocin(pre-dose to 8-hours post-dose)
- Time to Maximum Plasma Concentration (Tmax) of Psilocin(Pre-dose to 8 hours post-dose)
- Area Under the Curve (AUC₀-₈) for Psilocin(Pre-dose to 8 hours post-dose)
研究者
Suzanne "Sue" Sisley MD
Principal Investigator
Scottsdale Research Institute
研究点 (3)
Loading locations...
相似试验
招募中
Unknown
Psilocybin administration for treatment-resistant depressiodepressionD061218Treatment-resistant depressionJPRN-jRCTs031230351chida Hiroyuki12
已完成
2 期
Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study.2023-506647-42-00Centre Hospitalier Universitaire De Nimes, Centre Hospitalier Universitaire De Nimes30
招募中
2 期
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung CancerNCT07216404Alan Davis10
进行中（未招募）
1 期
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCDObsessive-Compulsive DisorderNCT06299319Centre for Addiction and Mental Health10
进行中（未招募）
1 期
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)Depression, AnxietyDistress, EmotionalNCT04754061Ottawa Hospital Research Institute20